Introduction
Methods
Data source
Definition of AMI population
Study population
Characteristics | Control group (N = 2672) | DPP-4 inhibitor group (N = 2672) | P value |
---|---|---|---|
Gender | |||
Female | 1098 (41.09%) | 1098 (41.09%) | 1 |
Male | 1574 (58.91%) | 1574 (58.91%) | |
Age | |||
Age <65 | 1064 (39.82%) | 1059 (39.63%) | 0.8468 |
65 ≤ age < 75 | 707 (26.46%) | 725 (27.13%) | |
Age ≥75 | 901 (33.72%) | 888 (33.23%) | |
Comorbidities | |||
Hypertension | 2016 (75.45%) | 2005 (75.04%) | 0.7274 |
Dyslipidemia | 1996 (74.7%) | 1996 (74.7%) | 1 |
Peripheral vascular disease | 144 (5.39%) | 144 (5.39%) | 1 |
Heart failure | 971 (36.34%) | 994 (37.2%) | 0.5141 |
End stage renal disease | 187 (7%) | 187 (7%) | 1 |
COPD | 231 (8.65%) | 234 (8.76%) | 0.8842 |
Cerebrovascular accident | 789 (29.53%) | 796 (29.79%) | 0.8339 |
Operations | |||
Percutaneous coronary intervention | 1699 (63.59%) | 1699 (63.59%) | 1 |
Coronary artery bypass graft | 260 (9.73%) | 297 (11.12%) | 0.0976 |
IABP | 240 (8.98%) | 248 (9.28%) | 0.704 |
Medication | |||
Aspirin | 2330 (87.2%) | 2440 (91.32%) | <0.0001 |
Clopidogrel | 2350 (87.95%) | 2454 (91.84%) | <0.0001 |
Any anti-platelet drug | 2513 (94.05%) | 2596 (97.16%) | <0.0001 |
ACEI or ARB | 1743 (65.23%) | 2007 (75.11%) | <0.0001 |
Statin | 1616 (60.48%) | 1780 (66.62%) | <0.0001 |
β-Blocker | 1587 (59.39%) | 1884 (70.51%) | <0.0001 |
CCB | 980 (36.68%) | 1145 (42.85%) | <0.0001 |
Heparin or low molecular weight heparin | 2174 (81.36%) | 2266 (84.81%) | 0.0008 |
Spironolactone | 468 (17.51%) | 615 (23.02%) | <0.0001 |
Nitrate | 2245 (84.02%) | 2366 (88.55%) | <0.0001 |
Nicorandil | 284 (10.63%) | 401 (15.01%) | <0.0001 |
α-Glucosidase | 197 (7.37%) | 602 (22.53%) | <0.0001 |
Glinides | 311 (11.64%) | 644 (24.1%) | <0.0001 |
Metformin | 781 (29.23%) | 1168 (43.71%) | <0.0001 |
Sulfonylureas | 778 (29.12%) | 1420 (53.14%) | <0.0001 |
Outcome analysis
Statistical analysis
Results
Characteristics (all, N = 5344) | HR (95% CI) |
---|---|
Sex (male vs female) | 0.98 (0.89–1.07) |
Age (65 ≤ age < 75 vs age <65) | 1.71 (1.5–1.96)*** |
Age (age ≥75 vs age <65) | 2.51 (2.2–2.85)*** |
Hypertension (yes vs no) | 1.2 (1.06–1.37)** |
Peripheral vascular disease (yes vs no) | 1.57 (1.34–1.84)*** |
Heart failure (yes vs no) | 1.35 (1.23–1.49)*** |
End stage renal disease (yes vs no) | 1.76 (1.51–2.06)*** |
Cerebrovascular disease (yes vs no) | 1.33 (1.21–1.47)*** |
Chronic obstructive pulmonary disease (yes vs no) | 1.33 (1.16–1.52)*** |
Percutaneous coronary intervention (yes vs no) | 0.54 (0.49–0.6)*** |
Any antiplatelet (yes vs no) | 0.58 (0.49–0.7)*** |
ACEI or ARB (yes vs no) | 0.72 (0.65–0.8)*** |
β-Blocker (yes vs no) | 0.79 (0.71–0.87)*** |
Heparin or low molecular weight heparin (yes vs no) | 1.02 (0.91–1.15) |
α-Glucosidase (yes vs no) | 0.95 (0.83–1.08) |
Glinides (yes vs no) | 1.05 (0.94–1.18) |
Metformin (yes vs no) | 0.77 (0.68–0.86)*** |
Sulfonylureas (yes vs no) | 0.91 (0.82–1.01) |
Thiazolidinedione (yes vs no) | 0.79 (0.59–1.04) |
DPP-4 inhibitor (yes vs no) | 0.86 (0.78–0.95)** |